The dose of 3 mg/kg administered every 3 weeks for a maximum of four infusions was initially validated in a 3-arm phase III study comparing ipilimumab with gp100 and a combination of both agents among 676 patients with advanced melanoma 16. Here, PMEL is linked to melanoma.